FindTrial
Sign In

210 mg brodalumab

DRUG5 trials

Sponsors

Bausch Health Americas, Inc.

Conditions

Moderate to Severe Plaque PsoriasisPlaque PsoriasisPsoriasisPsoriatic Arthritis

Phase 3

Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects
TerminatedNCT01708590
Bausch Health Americas, Inc.Psoriasis
Start: 2012-08-31End: 2015-08-31Updated: 2020-01-03
P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis
TerminatedNCT01708603
Bausch Health Americas, Inc.Moderate to Severe Plaque Psoriasis
Start: 2012-08-31End: 2015-10-31Updated: 2020-01-06
Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
TerminatedNCT01708629
Bausch Health Americas, Inc.Plaque Psoriasis
Start: 2012-09-30End: 2015-10-31Updated: 2020-01-03
Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis
CompletedNCT02024646
Bausch Health Americas, Inc.Psoriatic Arthritis
Start: 2014-03-31End: 2015-10-31Updated: 2020-08-20
Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis
TerminatedNCT02029495
Bausch Health Americas, Inc.Psoriatic Arthritis
Start: 2014-03-31End: 2015-10-31Updated: 2017-05-19

Related Papers

Keeping It Real: Real-World Brodalumab Outcomes in the Context of Pivotal Trials for Moderate-to-Severe Plaque Psoriasis
SKIN The Journal of Cutaneous Medicine2026-09-08
Reviewing the Link Between Psoriasis and High Body Mass Index: Focus on IL-17–Mediated Pathology and Anti–IL-17 Therapy
SKIN The Journal of Cutaneous Medicine2026-09-08
Efficacy and Safety of Brodalumab in Participants With Moderate-to-Severe Plaque Psoriasis: The Patient Journey
SKIN The Journal of Cutaneous Medicine2026-05-11
Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses.
2024-09-124 citations
Increased Skin Clearance and Quality of Life Improvement with Brodalumab Compared with Ustekinumab in Psoriasis Patients with Aggravating Lifestyle Factors.
2021-10-026 citations
Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials.
2020-10-2691 citations
Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE‐2 and ‐3
Journal of the European Academy of Dermatology and Venereology2020-07-1418 citations
Malignancy Rates in Brodalumab Clinical Studies for Psoriasis
American Journal of Clinical Dermatology2020-03-2318 citations
Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials.
2019-04-0124 citations
Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.
2018-12-2727 citations
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
2016-06-23340 citations
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
New England Journal of Medicine2015-09-30790 citations